Efficacy of the Memory Motivation (MEMO) Web Application Training

Not Applicable

Completed

• Conditions: Neurocognitive Disorders
• Interventions: Device: MeMo web application; Other: Control group

• Registration Number: NCT04142801
• Lead Sponsor: Innovation Alzheimer

Brief Summary

Memory, attentional, and behavioural symptoms are the clinical hallmarks of Neurocognitive disorders (NCD) such as Alzheimer's disease and related disorders. The World Health Organisation (WHO) guidelines for risk reduction of cognitive decline and dementia indicate that Cognitive training may be offered to older adults with normal cognition and with mild cognitive impairment to reduce the risk of cognitive decline and/or dementia. The use of Information and Communication Technologies (ICT) in the health domain is progressively expanding. The Alzheimer Innovation Association have developed MeMo (Memory Motivation) a free web application that can be used at home by patients.

The objective of the present study was to assess the effectiveness of employing the MeMo platform on cognitive performance in patients suffering from NCD.

Detailed Description

The objective of this study is to evaluate the effectiveness of the MeMo cognitive training exercise platform in patients suffering from neurocognitive disorders. These exercises ,have been developed by the association Innovation Alzheimer and the CoBTeK research team, located with the Nice memory Center at the Institut Claude Pompidou. MeMo can be used freely at home by patients. More specifically, it is a randomized controlled study that aims to compare the evolution of activities cognition and behavior between patients not using these exercises, and patients using these exercises for 12 weeks, 4 sessions per week.

Study Timeline

• Study Start: 2017-05-05
• Primary Completion: 2019-02-02
• Study Completion: 2019-08-10
• Status Verified: 2019-10
• Study First Submitted: 2019-10-19
• Study First Submitted QC: 2019-10-26
• Last Update Submitted: 2019-10-26
• Study First Posted: 2019-10-29
• Last Update Posted: 2019-10-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 49

Inclusion Criteria

• Outpatient consulting the Memory center
• older than 60 years old
• Mini Mental State examination score (MMSE) between 16 and 28 / 30
• met the DSM 5 diagnoses of mild neurocognitive disorders (mild NCD) or major neurocognitive disorders (Major NCD).

Exclusion Criteria

• Patients not able to read and write French
• presence of a hearing or major visual impairment
• a history of premorbid mental retardation
• had already used the MeMo application
• were presently involved in structured memory training activities.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
MeMo group	MeMo web application	MeMo group: experimental: regular use at home of the Memo web application In the Memo group patients were instructed on how to use the application, and allowed to train for 12 weeks. It was also explained that this training needed to be done regularly on a basis of 4 sessions of 30 minutes each per week.
Control group	Control group	Regular follow up at the memory center without cognitive training

Primary Outcome Measures

Name	Time	Method
Change is being assessed with the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)	Base line, Week 12	To score the IQCODE, add up the score for each question and divide by the number of questions. For the long IQCODE, divide by 26.

Secondary Outcome Measures

Name	Time	Method
Change in attention is is being assessed with the DSST	Base line, Week 12	Digit Symbol Substitution Test (attentional task)
Change in frontal functioning is being assessed with the FAB	Base line, Week 12	the Frontal Assessment Battery: Score 0 (healthy) - 18 (pathology)
IA-C	Base line, Week 12	Change in motivation is being assessed with theApathy inventory, clinician version score 0 (healthy)- 12 (pathology)
Change in behavior is being assessed with the NPI	Base line, Week 12	Neuropsychiatric Inventory score 0 (healthy) - 134 (pathology)

Trial Locations

Locations (1)

CoBtek lab, Institut Claude Pompidou; 🇫🇷 Nice, France